Deere & Company vs Viatris Inc — how do they compare? Deere & Company trades at $616.67 (market cap $164.47B), while Viatris Inc trades at $16.28 (market cap $18.69B). The key difference: Deere & Company is far larger — about 8.8× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.95%). Which is the better fit depends on your goals.
| DE | VTRS | |
|---|---|---|
Market Cap | $164.47B | $18.69B |
Sector | Industrials | Health |
52-Week High | $662.49 | $17.86 |
52-Week Low | $439.11 | $9.49 |
Enterprise Value | $219.29B | $30.81B |
Dividend Yield | 1.06% | 2.95% |
Signals from Pluang's Aura AI — not financial advice
Deere & Company (DE) trades at $620.83, up 0.97% for the day, with a bullish technical outlook supported by moving averages and recent earnings beats. Revenue declined to $44.67B in 2025, but net income margins remain healthy at 10.33%. The stock is near its pivot point of $620, with support at $613 and resistance at $628. Analyst consensus is a Moderate Buy with a $676.08 price target, reflecting optimism despite cyclical headwinds in agricultural equipment demand.
The outlook is cautiously positive, driven by consistent earnings outperformance and strong institutional holdings, but investors face risks from revenue volatility and high debt levels. The stock offers value if agricultural recovery materializes, but macroeconomic sensitivity warrants monitoring.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Deere is the world's leading manufacturer of agricultural equipment, producing some of the most recognizable machines in the heavy machinery industry. The company is divided into four reportable segments: production and precision agriculture, small agriculture and turf, construction and forestry, and John Deere Capital. Its products are available through an extensive dealer network, which includes over 1,900 dealer locations in North America and approximately 3,700 locations globally. John Deere Capital provides retail financing for machinery to its customers, in addition to wholesale financing for dealers, which increases the likelihood of Deere product sales.
Read more on DE →Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →